Last reviewed · How we verify
Romidepsin cycle 3
At a glance
| Generic name | Romidepsin cycle 3 |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (PHASE1)
- Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL (PHASE2)
- Study of Pembrolizumab (MK-3475) in Combination With Romidepsin (PHASE1, PHASE2)
- Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (PHASE1, PHASE2)
- Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Romidepsin Maintenance After Allogeneic Stem Cell Transplantation (PHASE1)
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (PHASE1)
- Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Romidepsin cycle 3 CI brief — competitive landscape report
- Romidepsin cycle 3 updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI